Abstract:Abstract Background Dementia-like cognitive impairment is an increasingly reported complication of SARS-CoV-2 infection. However, the underlying mechanisms responsible for this complication remain unclear. A better understanding of causative processes by which COVID-19 may lead to cognitive impairment is essential for developing preventive and therapeutic interventions. Methods In this study, we conducted a network-based, multimodal omics comparison of COVID-19 and neurologic complications. We constructed the SARS-CoV-2 virus-host interactome from protein-protein interaction assay and CRISPR-Cas9-based genetic assay results and compared network-based relationships therein with those of known neurological manifestations using network proximity measures. We also investigated the transcriptomic profiles (including single-cell/nuclei RNA-sequencing) of Alzheimer’s disease (AD) marker genes from patients infected with COVID-19, as well as the prevalence of SARS-CoV-2 entry factors in the brains of AD patients not infected with SARS-CoV-2. Results We found significant network-based relationships between COVID-19 and neuroinflammation and brain microvascular injury pathways and processes which are implicated in AD. We also detected aberrant expression of AD biomarkers in the cerebrospinal fluid and blood of patients with COVID-19. While transcriptomic analyses showed relatively low expression of SARS-CoV-2 entry factors in human brain, neuroinflammatory changes were pronounced. In addition, single-nucleus transcriptomic analyses showed that expression of SARS-CoV-2 host factors ( BSG and FURIN ) and antiviral defense genes ( LY6E , IFITM2 , IFITM3 , and IFNAR1 ) was elevated in brain endothelial cells of AD patients and healthy controls relative to neurons and other cell types, suggesting a possible role for brain microvascular injury in COVID-19-mediated cognitive impairment. Overall, individuals with the AD risk allele APOE E4/E4 displayed reduced expression of antiviral defense genes compared to APOE E3/E3 individuals. Conclusion Our results suggest significant mechanistic overlap between AD and COVID-19, centered on neuroinflammation and microvascular injury. These results help improve our understanding of COVID-19-associated neurological manifestations and provide guidance for future development of preventive or treatment interventions, although causal relationship and mechanistic pathways between COVID-19 and AD need future investigations.

The viral hypothesis in Alzheimer's disease: SARS-CoV-2 on the cusp

COVID-19 and Alzheimer's Disease: How One Crisis Worsens the Other.

Viral Infections, Are They a Trigger and Risk Factor of Alzheimer's Disease?

Amyloid precursor protein facilitates SARS-CoV-2 virus entry into cells and enhances amyloid-β-associated pathology in APP/PS1 mouse model of Alzheimer’s disease

Amyloid precursor protein facilitates SARS-CoV-2 virus entry into cells and enhances amyloid--associated pathology in APP/PS1 mouse model of Alzheimer's disease

Links between COVID-19 and Alzheimer's Disease-What Do We Already Know?

Investigating the Potential Shared Molecular Mechanisms between COVID-19 and Alzheimer's Disease via Transcriptomic Analysis

The emerging mechanism behind viral infections and extracellular vesicles hypotheses leading to neuroinflammation and Alzheimer's disease pathology

From Viral Infections to Alzheimer's Disease: Unveiling the Mechanistic Links Through Systems Bioinformatics

Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment

SARS-CoV-2 Exacerbates Beta-Amyloid Neurotoxicity, Inflammation and Oxidative Stress in Alzheimer’s Disease Patients

Viral Involvement in Alzheimer’s Disease

Ubiquity of the SARS-CoV-2 Receptor ACE2 and Upregulation in Limbic Regions of Alzheimer’s Disease Brain

Alzheimer's disease as a viral disease: Revisiting the infectious hypothesis

Plasma proteomic evidence for increased Alzheimer's disease-related brain pathology after SARS-CoV-2 infection

Accelerated amyloid deposition in SARS-CoV-2 infected mouse models of Alzheimer's disease

The Influence of SARS-CoV-2 Infection on the Development of Selected Neurological Diseases

Deterioration of neuroimmune homeostasis in Alzheimer's Disease patients who survive a COVID-19 infection

Emerging signs of Alzheimer‐like tau hyperphosphorylation and neuroinflammation in the brain post recovery from COVID‐19

Neuropathological findings in Down syndrome, Alzheimer's disease and control patients with and without SARS-COV-2: preliminary findings

Unravelling the connection between COVID-19 and Alzheimer's disease: a comprehensive review